# SLC18A2

## Overview
The SLC18A2 gene encodes the vesicular monoamine transporter 2 (VMAT2), a transmembrane protein that plays a critical role in the central nervous system by facilitating the transport of monoamine neurotransmitters into synaptic vesicles. VMAT2 is a member of the major facilitator superfamily (MFS) and is characterized by its 12 transmembrane helices, which are essential for its function in neurotransmitter storage and release. This protein is vital for maintaining neurotransmitter balance and preventing neurotoxic accumulation in the cytoplasm, thereby supporting normal synaptic transmission and neurological function. VMAT2's activity is crucial for processes such as mood regulation, reward processing, and motor control, making it a significant focus of research in the context of neurological and psychiatric disorders (Dalton2023Structural; Kraboth2021Involvement; Chen2022Identification).

## Structure
The SLC18A2 gene encodes the vesicular monoamine transporter 2 (VMAT2), a protein integral to the transport of monoamines into synaptic vesicles. VMAT2 is characterized by its 12 transmembrane (TM) helices, which are organized into two pseudosymmetric halves, each comprising six TM helices. These helices form the primary binding sites for neurotransmitters and inhibitors (Dalton2023Structural; Wang2024Transport). The protein adopts a canonical major facilitator superfamily (MFS) fold, with the N-domain consisting of TMs 1-6 and the C-domain of TMs 7-12 (Wang2024Transport).

The structure of VMAT2 includes specific residues critical for its function, such as W318, R189, K138, and N34, which are involved in drug binding and neurotransmitter transport (Dalton2023Structural). The protein's conformation is influenced by polar networks that play a role in proton coordination and transporter conformational changes, involving residues like D33, N34, and K138 (Dalton2023Structural).

VMAT2 lacks discernable extramembrane domains, and its structural characterization has been facilitated by cryo-electron microscopy, revealing its interactions with inhibitors like tetrabenazine (TBZ) (Dalton2023Structural; Wang2024Transport). The protein's structure is essential for understanding its role in neurotransmitter transport and the effects of pharmacological inhibitors.

## Function
The SLC18A2 gene encodes the vesicular monoamine transporter 2 (VMAT2), a crucial protein in the central nervous system responsible for the transport of monoamine neurotransmitters such as dopamine, serotonin, norepinephrine, and histamine into synaptic vesicles. This process is essential for the proper storage and regulated release of these neurotransmitters, which are critical for synaptic transmission and normal neurological function (Kraboth2021Involvement; Chen2022Identification).

VMAT2 operates by utilizing an electrochemical gradient to package neurotransmitters into vesicles within presynaptic neurons. This packaging is vital for maintaining neurotransmitter balance and preventing cytoplasmic accumulation, which can be neurotoxic (Hu2020The). In healthy human cells, VMAT2's activity supports dopamine signaling by enabling exocytosis and maintaining cellular health, thus playing a neuroprotective role, particularly in dopaminergic neurons (Kraboth2021Involvement).

The proper functioning of VMAT2 is crucial for mood regulation, reward processing, and motor control, as it ensures the availability of neurotransmitters for release into the synaptic cleft, where they can bind to postsynaptic receptors and propagate neural signals (Chen2022Identification).

## Clinical Significance
Mutations and alterations in the SLC18A2 gene, which encodes the vesicular monoamine transporter 2 (VMAT2), are associated with several neurological and psychiatric disorders. Homozygous mutations in SLC18A2 have been linked to infantile-onset dystonia-parkinsonism, mood disorders, and autonomic nervous system dysfunction. Affected individuals often show a beneficial response to dopamine agonists, while levodopa trials may have adverse effects (Keller2021Genetic). 

SLC18A2 mutations can also lead to brain monoamine vesicular transport disease, characterized by symptoms such as developmental delay, hypotonia, epilepsy, and uncontrolled movements. A specific missense variant, p.P316A, results in absent serotonin in platelets and various neurological symptoms (Padmakumar2019A).

Alterations in SLC18A2 expression levels are associated with Parkinson's disease. Lower VMAT2 levels increase the risk of Parkinson's, while certain genetic polymorphisms in the VMAT2 promoter region may offer a protective effect against the disease (Wang2024Tricyclic; Brighina2013Analysis). Variants in SLC18A2 are also linked to an increased risk of opioid dependence, with specific intronic SNPs showing significant associations (Randesi2019VMAT2).

## Interactions
The SLC18A2 gene encodes the vesicular monoamine transporter 2 (VMAT2), which is involved in the transport of monoamines into synaptic vesicles. VMAT2 interacts with several proteins that are crucial for its function and regulation. It interacts with adaptor complexes such as AP3 and PACS-1, which are involved in its trafficking from the Golgi apparatus to synaptic vesicles and large dense-core vesicles (Lawal2013SLC18:). The cytoplasmic C-terminal domain of VMAT2 contains specific motifs, including a dileucine motif and acidic residues, which are important for its localization and sorting (Lawal2013SLC18:).

VMAT2 also interacts with synaptophysin, a protein that enhances its neuroprotective effects, particularly in the context of neurotoxicity (Guillot2009Protective). This interaction is significant in maintaining neuronal health and protecting against neurodegenerative conditions. Additionally, VMAT2 is involved in a protein-protein interaction network related to Parkinson's disease, where it forms a cluster with other proteins such as NR4A2 and TH, indicating its role in the dopaminergic synapse pathway (Odumpatta2020Integrative). These interactions highlight the importance of VMAT2 in neurotransmitter regulation and its potential as a therapeutic target in neurodegenerative diseases.


## References


[1. (Wang2024Transport) Yuwei Wang, Pei Zhang, Yulin Chao, Zhini Zhu, Chuanhui Yang, Zixuan Zhou, Yaohui Li, Yonghui Long, Yuehua Liu, Dianfan Li, Sheng Wang, and Qianhui Qu. Transport and inhibition mechanism for vmat2-mediated synaptic vesicle loading of monoamines. Cell Research, 34(1):47–57, January 2024. URL: http://dx.doi.org/10.1038/s41422-023-00906-z, doi:10.1038/s41422-023-00906-z. This article has 6 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/s41422-023-00906-z)

[2. (Padmakumar2019A) Manisha Padmakumar, Jaak Jaeken, Vincent Ramaekers, Lieven Lagae, Daniel Greene, Chantal Thys, Chris Van Geet, NIHR BioResource, Kathleen Stirrups, Kate Downes, Ernest Turro, and Kathleen Freson. A novel missense variant in slc18a2 causes recessive brain monoamine vesicular transport disease and absent serotonin in platelets. JIMD Reports, 47(1):9–16, March 2019. URL: http://dx.doi.org/10.1002/jmd2.12030, doi:10.1002/jmd2.12030. This article has 25 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/jmd2.12030)

[3. (Odumpatta2020Integrative) Rajasree Odumpatta and Mohanapriya Arumugam. Integrative analysis of gene expression and regulatory network interaction data reveals the protein kinase c family of serine/threonine receptors as a significant druggable target for parkinson’s disease. Journal of Molecular Neuroscience, 71(3):466–480, July 2020. URL: http://dx.doi.org/10.1007/s12031-020-01669-7, doi:10.1007/s12031-020-01669-7. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s12031-020-01669-7)

[4. (Wang2024Tricyclic) Xunan Wang, Ilias Marmouzi, Peter S. B. Finnie, Meghan L. Bucher, Yuanye Yan, Erin Q. Williams, Svein I. Støve, Tatiana V. Lipina, Amy J. Ramsey, Gary W. Miller, and Ali Salahpour. Tricyclic and tetracyclic antidepressants upregulate vmat2 activity and rescue disease-causing vmat2 variants. Neuropsychopharmacology, 49(11):1783–1791, July 2024. URL: http://dx.doi.org/10.1038/s41386-024-01914-2, doi:10.1038/s41386-024-01914-2. This article has 0 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41386-024-01914-2)

[5. (Guillot2009Protective) Thomas S. Guillot and Gary W. Miller. Protective actions of the vesicular monoamine transporter 2 (vmat2) in monoaminergic neurons. Molecular Neurobiology, 39(2):149–170, March 2009. URL: http://dx.doi.org/10.1007/s12035-009-8059-y, doi:10.1007/s12035-009-8059-y. This article has 153 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s12035-009-8059-y)

[6. (Lawal2013SLC18:) Hakeem O. Lawal and David E. Krantz. Slc18: vesicular neurotransmitter transporters for monoamines and acetylcholine. Molecular Aspects of Medicine, 34(2–3):360–372, April 2013. URL: http://dx.doi.org/10.1016/j.mam.2012.07.005, doi:10.1016/j.mam.2012.07.005. This article has 110 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.mam.2012.07.005)

[7. (Brighina2013Analysis) Laura Brighina, Chiara Riva, Francesca Bertola, Enrico Saracchi, Silvia Fermi, Stefano Goldwurm, and Carlo Ferrarese. Analysis of vesicular monoamine transporter 2 polymorphisms in parkinson’s disease. Neurobiology of Aging, 34(6):1712.e9-1712.e13, June 2013. URL: http://dx.doi.org/10.1016/j.neurobiolaging.2012.12.020, doi:10.1016/j.neurobiolaging.2012.12.020. This article has 39 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.neurobiolaging.2012.12.020)

[8. (Chen2022Identification) Lin Chen, Yong Wang, Juan Huang, Binbin Hu, and Wei Huang. Identification of immune-related hub genes in parkinson’s disease. Frontiers in Genetics, July 2022. URL: http://dx.doi.org/10.3389/fgene.2022.914645, doi:10.3389/fgene.2022.914645. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fgene.2022.914645)

[9. (Randesi2019VMAT2) Matthew Randesi, Wim van den Brink, Orna Levran, Peter Blanken, Jan M van Ree, Jurg Ott, and Mary Jeanne Kreek. Vmat2 gene ( slc18a2 ) variants associated with a greater risk for developing opioid dependence. Pharmacogenomics, 20(5):331–341, April 2019. URL: http://dx.doi.org/10.2217/pgs-2018-0137, doi:10.2217/pgs-2018-0137. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.2217/pgs-2018-0137)

10. (Dalton2023Structural) Structural mechanisms for VMAT2 inhibition by tetrabenazine. This article has 2 citations.

[11. (Kraboth2021Involvement) Zoltán Kraboth, Bela Kajtár, Bence Gálik, Attila Gyenesei, Attila Miseta, and Bernadette Kalman. Involvement of the catecholamine pathway in glioblastoma development. Cells, 10(3):549, March 2021. URL: http://dx.doi.org/10.3390/cells10030549, doi:10.3390/cells10030549. This article has 6 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cells10030549)

[12. (Hu2020The) Chengliang Hu, Lei Tao, Xizhi Cao, and Ligong Chen. The solute carrier transporters and the brain: physiological and pharmacological implications. Asian Journal of Pharmaceutical Sciences, 15(2):131–144, March 2020. URL: http://dx.doi.org/10.1016/j.ajps.2019.09.002, doi:10.1016/j.ajps.2019.09.002. This article has 104 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.ajps.2019.09.002)

[13. (Keller2021Genetic) Ignacio Juan Keller Sarmiento and Niccolò Emanuele Mencacci. Genetic dystonias: update on classification and new genetic discoveries. Current Neurology and Neuroscience Reports, February 2021. URL: http://dx.doi.org/10.1007/s11910-021-01095-1, doi:10.1007/s11910-021-01095-1. This article has 34 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1007/s11910-021-01095-1)